Sartorius Stedim Biotech S.A.: Proposals by the Board of Directors to the AGM

Regulatory News:

At yesterday’s meeting, the Board of Directors of Sartorius Stedim Biotech S.A. (Paris:DIM) resolved to submit a proposal to the Annual General Shareholders' Meeting (AGM) on April 8, 2014, to pay a dividend of €1.20 per share for fiscal 2013. Compared with a year earlier, dividends per share would increase by 9.1% from €1.10, while total profit distributed would rise from €16.9 million to €18.4 million.

Moreover, the Board of Directors decided to submit resolutions to the Shareholder Meeting for delegating authority to the Board to increase share capital by issuing up to 2 million new shares in order to facilitate future growth and expansion of the SSB Group. At the same time, the Shareholder Meeting shall grant to the board the authority to cancel the company’s approximately 1.7 million treasury shares.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,300 people, and in 2013 earned sales revenue of 588.4 million euros.